Drugs / PT010
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03075267 | Apr → Sep 2017 | chronic obstructive pulmonary disease | Pearl Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02189304 | Jun → Sep 2014 | chronic obstructive pulmonary disease | Pearl Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PT010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02189304 ↗ |
| Known as | BGF MDI | “PT010 (BGF MDI) 320/14.4/9.6 µg” NCT03075267 ↗ |
| Route | Inhaled | “Budesonide, Glycopyrronium, Formoterol Metered Dose Inhaler” NCT03075267 ↗ |